No phaseCompleted
From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 (ASD/NF1inhib)
Linking Inhibition From Molecular to Systems and Cognitive Levels: a Preclinical and Clinical Approach in Autism Spectrum Disorders and Neurofibromatosis.
- Sponsor
- University of Coimbra (Academic or other)
- Enrolment
- 16 enrolled
- Conditions
- Autism Spectrum Disorder; Neurofibromatosis 1
- Interventions
- Lovastatin 60 MG; Placebos
- Ages
- children, adults, older adults
- Registry
- NCT03826940
From the registry
This study aims to investigate synaptic physiology and behavioral inhibition in patients with NF1 and ASD and to answer whether inhibitory deficits at these levels are modulated by lovastatin. Structure: (1) Visit 1: Baseline assessment- participant's characterization, baseline outcome measures and additional evaluations, (2) 3 consecutive days of physiologically probing drug/placebo intake, (3) Visit 2: Outcome measures and additional evaluations in the day after the last drug/placebo intake, (4) Washout period of 4 to 6 weeks, (5) 3 consecutive days of drug/placebo intake, (6) Visit 3: Outcome measures and additional evaluations in the day after the last placebo/drug intake.
Primary outcomes
- Neurochemical response changes to GABAergic stimulation